The FDA last week approved Incyte’s Pemazyre for the treatment of elapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement, a rare and aggressive form of blood cancer, in adult patients. The selective fibroblast growth factor receptor (FGFR) inhibitor was first approved in April 2020 to treat cholangiocarcinoma, a rare bile duct cancer. For this indication, it holds covered or better status for 89% of lives under the pharmacy benefit. Evaluate Pharma projects Pemazyre will be Incyte’s no. 4 bestselling drug in 2028, bringing in $197 million in total global sales. Evaluate reported global Pemazyre sales of $69 million for 2021.